Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)
LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)

NCT05677308

CompletedN/A

Sponsor: AstraZeneca

Conditions: Breast Cancer

Countries: Japan

To evaluate the frequency of bone marrow suppression Adverse Drug Reactions (ADRs) in patients with BRCA mutated HER2 negative high recurrent risk breast cancer treated with LYNPARZA for adjuvant treatment in the actual post-marketing use.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* The patients who started treatment with LYNPARZA for the first time for the approved indication "Adjuvant treatment for patients with BRCA-mutated HER2 negative high recurrent risk breast cancer"

Exclusion Criteria:

* Patients who have no treatment history with LYNPARZA
Locations (38)
  • Aichi, Japan
  • Akita, Japan
  • Aomori, Japan
  • Chiba, Japan
  • Ehime, Japan
  • Fukui, Japan
  • Fukuoka, Japan
  • Gifu, Japan
  • Gunma, Japan
  • Hiroshima, Japan
  • Hokkaido, Japan
  • Hyōgo, Japan
  • Ibaraki, Japan
  • Ishikawa, Japan
  • Kanagawa, Japan
  • Kochi, Japan
  • Kumamoto, Japan
  • Kyoto, Japan
  • Mie, Japan
  • Miyagi, Japan
  • Nara, Japan
  • Niigata, Japan
  • Numakunai, Japan
  • Okayama, Japan
  • Okinawa, Japan
  • Osaka, Japan
  • Ōita, Japan
  • Saga, Japan
  • Saitama, Japan
  • Shiga, Japan
  • + 8 more on CT.gov